{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:00:05Z","timestamp":1791201605152,"version":"4.2.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.rceng.2026.502620","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:53:58Z","timestamp":1790096038000},"page":"502620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Utility of an extended 12-autoantibody panel in systemic sclerosis: Clinical and prognostic implications in a real-life cohort"],"prefix":"10.1016","author":[{"given":"P.","family":"L\u00f3pez de Turiso Giner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1012-4157","authenticated-orcid":false,"given":"L.","family":"Fumanal Idocin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mart\u00ednez-Lostao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Corredor S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"S\u00e1ez C\u00f3met","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Velilla Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rceng.2026.502620_bib0005","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rceng.2026.502620_bib0010","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s12016-022-08946-w","article-title":"Systemic sclerosis-specific antibodies: novel and classical biomarkers","volume":"64","author":"Cavazzana","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.rceng.2026.502620_bib0015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/2397198318783930","article-title":"Anti-nuclear autoantibodies in systemic sclerosis: news and perspectives","volume":"3","author":"Hamaguchi","year":"2018","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.rceng.2026.502620_bib0020","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rceng.2026.502620_bib0025","first-page":"80","article-title":"The clinical relevance of autoantibodies in scleroderma","volume":"5","author":"Ho","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rceng.2026.502620_bib0030","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rceng.2026.502620_bib0035","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0889-857X(05)70297-0","article-title":"Antinuclear antibody in systemic sclerosis (scleroderma)","volume":"22","author":"Okano","year":"1996","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.rceng.2026.502620_bib0040","article-title":"Comprehensive autoantibody profiles in systemic sclerosis: clinical cluster analysis","volume":"13","author":"H\u00f6ppner","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.rceng.2026.502620_bib0045","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1002\/art.39316","article-title":"Interpretation of an extended autoantibody profile in a well-characterized Australian Systemic Sclerosis (Scleroderma) Cohort using principal components analysis","volume":"67","author":"Patterson","year":"2015","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.rceng.2026.502620_bib0050","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rceng.2026.502620_bib0055","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13075-019-1867-1","article-title":"Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature","volume":"21","author":"Pokeerbux","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rceng.2026.502620_bib0060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rceng.2026.502620_bib0065","first-page":"41","article-title":"Clinical features of systemic sclerosis patients with anti-RNA polymerase III antibody in a single centre in Spain","volume":"37","author":"Callejas-Moraga","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rceng.2026.502620_bib0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.5301\/jsrd.5000209","article-title":"Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes","volume":"1","author":"Peoples","year":"2016","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.rceng.2026.502620_bib0075","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s10067-018-4182-3","article-title":"The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink","volume":"37","author":"Royle","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rceng.2026.502620_bib0080","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/rheumatology\/keg033","article-title":"Mortality and prognostic factors in Spanish patients with systemic sclerosis","volume":"42","author":"Sime\u00f3n","year":"2003","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.rceng.2026.502620_bib0085","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.autrev.2008.06.010","article-title":"Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies","volume":"7","author":"Koenig","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.rceng.2026.502620_bib0090","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","article-title":"Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database","volume":"71","author":"Meier","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rceng.2026.502620_bib0095","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3390\/jcm12020657","article-title":"Autoantibodies and clinical correlations in polish systemic sclerosis patients: a cross-sectional study","volume":"12","author":"\u017bebryk","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.rceng.2026.502620_bib0100","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1136\/annrheumdis-2015-207271","article-title":"Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database","volume":"75","author":"Wirz","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rceng.2026.502620_bib0105","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rceng.2026.502620_bib0110","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.semarthrit.2011.10.004","article-title":"Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status","volume":"41","author":"Sime\u00f3n-Aznar","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rceng.2026.502620_bib0115","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s10067-018-4390-x","article-title":"Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry","volume":"38","author":"Garc\u00eda-Hern\u00e1ndez","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rceng.2026.502620_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.medcli.2015.04.029","article-title":"[Screening of pulmonary hypertension in a Spanish cohort of patients with systemic sclerosis]","volume":"146","author":"Garc\u00eda Hern\u00e1ndez","year":"2016","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.rceng.2026.502620_bib0125","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/rheumatology\/kep290","article-title":"Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay","volume":"48","author":"Satoh","year":"2009","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.rceng.2026.502620_bib0130","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/1346-8138.12722","article-title":"Demographic and clinical features of systemic sclerosis patients with anti-RNA polymerase III antibodies","volume":"42","author":"Motegi","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.rceng.2026.502620_bib0135","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3899\/jrheum.160867","article-title":"Cardiopulmonary disease development in anti-RNA polymerase III-positive systemic sclerosis: comparative analyses from an unselected, prospective patient cohort","volume":"44","author":"Hoffmann-Vold","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rceng.2026.502620_bib0140","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1186\/ar3544","article-title":"Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort","volume":"13","author":"Nikpour","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rceng.2026.502620_bib0145","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rceng.2026.502620_bib0150","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1186\/ar3763","article-title":"Clinical significance of antibodies to Ro52\/TRIM21 in systemic sclerosis","volume":"14","author":"Hudson","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rceng.2026.502620_bib0155","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/03009742.2021.1887927","article-title":"Anti-Ro52\/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients","volume":"50","author":"Lee","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.rceng.2026.502620_bib0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103536","article-title":"Prevalence of anti-Ro52-kDa\/SSA (TRIM21) antibodies and associated clinical phenotype in systemic sclerosis: data from a French cohort, a systematic review and meta-analysis","volume":"23","author":"Martel","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.rceng.2026.502620_bib0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152810","article-title":"Dual positivity for anti-Ro52 and anti-Ro60 antibodies is linked to greater organ involvement and disease progression in systemic sclerosis","volume":"74","author":"Yin","year":"2025","journal-title":"Semin Arthritis Rheum"},{"issue":"4 Suppl 91","key":"10.1016\/j.rceng.2026.502620_bib0170","first-page":"S131","article-title":"Monospecific anti-Ro52\/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival","volume":"33","author":"Wodkowski","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"6 Suppl 86","key":"10.1016\/j.rceng.2026.502620_bib0175","article-title":"Anti-SSA\/Ro52 autoantibodies in scleroderma: results of an observational, cross-sectional study","volume":"32","author":"S\u00e1nchez-Montalv\u00e1","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rceng.2026.502620_bib0180","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","article-title":"Antinuclear antibodies in systemic sclerosis: an update","volume":"58","author":"Stochmal","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.rceng.2026.502620_bib0185","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3899\/jrheum.160574","article-title":"Antifibrillarin antibodies are associated with native North American ethnicity and poorer survival in systemic sclerosis","volume":"44","author":"Mejia Otero","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rceng.2026.502620_bib0190","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.41493","article-title":"Cancer in systemic sclerosis: analysis of antibodies against components of the Th\/To complex","volume":"73","author":"Mecoli","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rceng.2026.502620_bib0195","first-page":"1589","article-title":"Anti-Th\/To antibodies in systemic sclerosis: analysis of long-term follow-up of pulmonary involvement, organ damage accrual and mortality in an Italian cohort with a case-control study","volume":"41","author":"Moschetti","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rceng.2026.502620_bib0200","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejim.2024.03.035","article-title":"Clinical significance of the anti-Nucleolar Organizer Region 90 antibodies (NOR90) in systemic sclerosis: analysis of the European Scleroderma Trials and Research (EUSTAR) cohort and a systematic literature review","volume":"125","author":"Dima","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.rceng.2026.502620_bib0205","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1365-2249.1999.00961.x","article-title":"Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis","volume":"117","author":"Ihn","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.rceng.2026.502620_bib0210","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3109\/08916934.2015.1077231","article-title":"Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects","volume":"48","author":"Wodkowski","year":"2015","journal-title":"Autoimmunity"},{"key":"10.1016\/j.rceng.2026.502620_bib0215","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1093\/rheumatology\/keab152","article-title":"The clinical phenotype of systemic sclerosis patients with anti-PM\/Scl antibodies: results from the EUSTAR cohort","volume":"60","author":"Lazzaroni","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.rceng.2026.502620_bib0220","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004713","article-title":"Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations","volume":"95","author":"Hoa","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.rceng.2026.502620_bib0225","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1136\/ard.2007.073981","article-title":"Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study","volume":"67","author":"Rozman","year":"2008","journal-title":"Ann Rheum Dis"}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887426001360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887426001360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:35:21Z","timestamp":1791200121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2254887426001360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":45,"alternative-id":["S2254887426001360"],"URL":"https:\/\/doi.org\/10.1016\/j.rceng.2026.502620","relation":{},"ISSN":["2254-8874"],"issn-type":[{"value":"2254-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utility of an extended 12-autoantibody panel in systemic sclerosis: Clinical and prognostic implications in a real-life cohort","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rceng.2026.502620","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2026.502620","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Medicina Interna (SEMI). All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"502620"}}